Nifty
:
24765.90
Sensex
:
80015.90
285.40 (1.17%)
899.71 (1.14%)
Nifty
Sensex
:
:
24765.90
80015.90
285.40 (1.17%)
899.71 (1.14%)

Zydus Lifesciences Ltd.

Pharmaceuticals & Drugs - Global

Rating :
75/99

BSE: 532321 | NSE: ZYDUSLIFE

NSE BSE
914.65
05-Mar-2026
  • Open
  • High
  • Low
  • Previous Close
  •  900
  •  918
  •  898.1
  •  896.90
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  465436
  •  424245449.2
  •  1059.05
  •  795

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 92,015.07
  • 18.27
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 98,826.47
  • 1.20%
  • 3.43

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 75.00%
  • 0.56%
  • 5.54%
  • FII
  • DII
  • Others
  • 7.06%
  • 10.83%
  • 1.01%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.44
  • 10.04
  • 10.48

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.46
  • 15.28
  • 14.05

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.98
  • 15.71
  • 33.68

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.33
  • 22.82
  • 23.39

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.64
  • 3.71
  • 4.11

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.21
  • 14.75
  • 14.84

Earnings Forecasts:

(Updated: 28-02-2026)
Description
2024
2025
2026
2027
Adj EPS
44.97
45.27
42.21
46.32
P/E Ratio
20.34
20.20
21.67
19.75
Revenue
22573.8
26317.4
28447
30687.7
EBITDA
6895.1
7065.46
6894.54
7430.58
Net Income
4525.5
4610.75
4288.37
4702.23
ROA
13.61
11.95
9.84
9.61
P/B Ratio
3.84
3.30
2.93
2.60
ROE
20.67
17.39
14.49
14.19
FCFF
5157.1
-9.84
3760.83
3927.08
FCFF Yield
5.71
-0.01
4.16
4.35
Net Debt
-4594.7
-1370.25
-4359.37
-6440.05
BVPS
238.05
277.37
312.16
351.25

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Net Sales
6,864.50
5,269.10
30.28%
6,123.20
5,237.00
16.92%
6,573.70
6,207.50
5.90%
6,527.90
5,533.80
17.96%
Expenses
5,048.10
3,881.50
30.06%
4,521.50
3,821.00
18.33%
4,542.30
4,123.50
10.16%
4,402.40
3,908.60
12.63%
EBITDA
1,816.40
1,387.60
30.90%
1,601.70
1,416.00
13.11%
2,031.40
2,084.00
-2.52%
2,125.50
1,625.20
30.78%
EBIDTM
26.46%
26.33%
26.16%
27.04%
30.90%
33.57%
32.56%
29.37%
Other Income
111.40
57.50
93.74%
523.10
113.60
360.48%
212.00
63.20
235.44%
80.60
161.70
-50.15%
Interest
129.90
32.00
305.94%
101.30
25.10
303.59%
84.70
32.20
163.04%
76.60
34.60
121.39%
Depreciation
359.60
229.00
57.03%
301.90
233.60
29.24%
238.10
215.30
10.59%
237.90
205.30
15.88%
PBT
1,353.40
1,184.10
14.30%
1,687.40
1,270.90
32.77%
1,920.60
1,899.70
1.10%
1,672.00
1,547.00
8.08%
Tax
388.30
179.50
116.32%
454.00
373.10
21.68%
434.00
436.10
-0.48%
423.20
321.20
31.76%
PAT
965.10
1,004.60
-3.93%
1,233.40
897.80
37.38%
1,486.60
1,463.60
1.57%
1,248.80
1,225.80
1.88%
PATM
14.06%
19.07%
20.14%
17.14%
22.61%
23.58%
19.13%
22.15%
EPS
10.36
10.17
1.87%
12.51
9.06
38.08%
14.58
14.11
3.33%
11.64
11.75
-0.94%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
26,089.30
23,241.50
19,547.40
17,237.40
15,109.90
14,403.50
14,253.10
13,165.60
11,904.90
9,376.50
9,426.80
Net Sales Growth
17.27%
18.90%
13.40%
14.08%
4.90%
1.06%
8.26%
10.59%
26.97%
-0.53%
 
Cost Of Goods Sold
7,013.40
5,345.40
5,260.10
5,335.70
4,757.00
4,094.20
4,243.30
4,141.30
3,656.90
3,065.00
2,673.20
Gross Profit
19,075.90
17,896.10
14,287.30
11,901.70
10,352.90
10,309.30
10,009.80
9,024.30
8,248.00
6,311.50
6,753.60
GP Margin
73.12%
77.00%
73.09%
69.05%
68.52%
71.57%
70.23%
68.54%
69.28%
67.31%
71.64%
Total Expenditure
18,514.30
16,348.00
14,248.40
13,665.50
11,935.20
11,018.20
11,472.90
10,187.20
9,057.50
7,472.30
7,097.30
Power & Fuel Cost
-
358.20
366.30
343.50
299.30
231.60
252.90
231.60
211.40
174.50
155.40
% Of Sales
-
1.54%
1.87%
1.99%
1.98%
1.61%
1.77%
1.76%
1.78%
1.86%
1.65%
Employee Cost
-
3,289.70
2,789.00
2,456.40
2,177.70
2,069.50
2,169.80
1,903.20
1,644.70
1,485.20
1,119.00
% Of Sales
-
14.15%
14.27%
14.25%
14.41%
14.37%
15.22%
14.46%
13.82%
15.84%
11.87%
Manufacturing Exp.
-
3,445.60
2,758.10
2,639.80
2,272.30
2,271.40
2,230.00
1,923.20
1,680.40
955.30
1,397.60
% Of Sales
-
14.83%
14.11%
15.31%
15.04%
15.77%
15.65%
14.61%
14.12%
10.19%
14.83%
General & Admin Exp.
-
933.50
625.00
620.30
506.70
357.90
582.60
462.60
398.70
466.00
356.40
% Of Sales
-
4.02%
3.20%
3.60%
3.35%
2.48%
4.09%
3.51%
3.35%
4.97%
3.78%
Selling & Distn. Exp.
-
2,362.20
1,800.10
1,674.60
1,373.30
1,444.70
1,468.40
1,154.10
1,129.40
916.80
1,078.30
% Of Sales
-
10.16%
9.21%
9.71%
9.09%
10.03%
10.30%
8.77%
9.49%
9.78%
11.44%
Miscellaneous Exp.
-
613.40
649.80
595.20
548.90
548.90
525.90
371.20
336.00
409.50
1,078.30
% Of Sales
-
2.64%
3.32%
3.45%
3.63%
3.81%
3.69%
2.82%
2.82%
4.37%
3.37%
EBITDA
7,575.00
6,893.50
5,299.00
3,571.90
3,174.70
3,385.30
2,780.20
2,978.40
2,847.40
1,904.20
2,329.50
EBITDA Margin
29.03%
29.66%
27.11%
20.72%
21.01%
23.50%
19.51%
22.62%
23.92%
20.31%
24.71%
Other Income
927.10
459.60
369.40
474.60
390.70
75.00
117.10
208.50
133.00
147.10
116.60
Interest
392.50
191.00
81.20
129.90
127.00
186.40
341.80
195.80
110.80
63.10
52.80
Depreciation
1,137.50
915.80
764.10
722.70
713.00
669.60
696.50
598.60
538.80
373.30
292.10
PBT
6,633.40
6,246.30
4,823.10
3,193.90
2,725.40
2,604.30
1,859.00
2,392.50
2,330.80
1,614.90
2,101.20
Tax
1,699.50
1,411.90
977.50
587.80
511.70
193.60
319.80
530.30
564.40
128.90
177.40
Tax Rate
25.62%
23.43%
20.33%
22.70%
18.03%
8.07%
21.39%
22.26%
24.21%
7.98%
8.45%
PAT
4,933.90
4,467.70
3,718.10
1,870.30
2,195.40
2,154.20
1,147.80
1,801.90
1,731.80
1,456.60
1,890.90
PAT before Minority Interest
4,846.10
4,614.80
3,831.40
2,001.90
2,326.40
2,205.60
1,175.60
1,851.80
1,766.40
1,485.70
1,921.30
Minority Interest
-87.80
-147.10
-113.30
-131.60
-131.00
-51.40
-27.80
-49.90
-34.60
-29.10
-30.40
PAT Margin
18.91%
19.22%
19.02%
10.85%
14.53%
14.96%
8.05%
13.69%
14.55%
15.53%
20.06%
PAT Growth
7.45%
20.16%
98.80%
-14.81%
1.91%
87.68%
-36.30%
4.05%
18.89%
-22.97%
 
EPS
49.03
44.40
36.95
18.59
21.82
21.41
11.41
17.91
17.21
14.48
18.79

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
23,953.10
19,829.50
17,515.80
16,999.60
12,992.30
10,375.70
10,386.30
8,744.50
6,960.00
5,699.20
Share Capital
100.60
100.60
101.20
102.40
102.40
102.40
102.40
102.40
102.40
102.40
Total Reserves
23,852.50
19,728.90
17,414.60
16,897.20
12,889.90
10,273.30
10,283.90
8,642.10
6,857.60
5,596.80
Non-Current Liabilities
-542.10
193.10
-725.00
-193.60
19.40
2,853.90
3,491.10
2,122.20
1,903.30
736.10
Secured Loans
0.00
0.00
0.00
0.00
0.00
1,953.60
2,332.80
200.60
319.60
393.80
Unsecured Loans
0.00
0.00
0.00
362.10
609.50
1,261.00
1,616.90
2,354.50
2,148.80
502.60
Long Term Provisions
383.90
309.70
271.80
325.00
309.50
235.20
184.10
155.90
151.20
120.70
Current Liabilities
9,041.60
5,339.70
5,526.70
7,826.80
7,861.30
8,269.40
7,342.50
6,072.00
5,305.80
3,461.00
Trade Payables
2,305.80
2,126.70
2,125.00
2,137.80
2,205.90
2,044.30
1,922.60
1,888.40
1,547.90
1,308.10
Other Current Liabilities
2,499.20
1,677.60
1,798.50
1,967.50
2,166.20
2,126.30
2,033.60
1,473.90
1,212.10
860.70
Short Term Borrowings
3,169.50
768.60
1,081.00
3,314.10
3,070.90
3,826.50
3,196.90
2,557.50
2,476.90
1,210.90
Short Term Provisions
1,067.10
766.80
522.20
407.40
418.30
272.30
189.40
152.20
68.90
81.30
Total Liabilities
34,857.90
27,634.40
24,490.00
26,687.00
22,810.30
22,833.70
22,512.80
17,129.70
14,325.20
10,032.10
Net Block
13,133.70
12,368.50
11,520.90
12,188.50
12,132.80
12,230.50
12,163.70
6,482.60
5,755.10
3,747.90
Gross Block
21,699.80
19,919.80
18,343.80
17,650.90
17,345.00
16,781.50
15,702.30
9,349.10
8,102.90
5,767.30
Accumulated Depreciation
8,566.10
7,551.30
6,822.90
5,462.40
5,212.20
4,551.00
3,538.60
2,866.50
2,345.80
2,016.80
Non Current Assets
17,811.80
16,135.20
14,477.60
14,438.20
14,094.30
14,118.30
14,014.70
8,911.00
8,302.90
5,751.70
Capital Work in Progress
2,691.90
2,423.30
1,200.70
725.90
783.20
741.50
837.20
1,527.20
1,543.30
950.80
Non Current Investment
1,556.70
968.00
927.30
934.80
631.20
552.20
443.60
470.90
385.70
217.10
Long Term Loans & Adv.
400.10
344.50
358.70
369.30
323.30
332.00
410.40
300.00
384.70
661.20
Other Non Current Assets
29.40
30.90
470.00
219.70
223.80
262.10
159.80
130.30
234.10
174.70
Current Assets
17,046.10
11,419.80
10,008.20
12,095.20
8,716.00
8,715.40
8,498.10
8,200.50
6,022.30
4,280.40
Current Investments
4,851.10
252.50
619.30
2,353.20
198.90
212.80
229.90
274.80
49.10
199.10
Inventories
3,944.00
3,441.90
3,413.30
3,719.40
3,236.20
2,789.00
2,688.00
2,385.30
1,803.70
1,337.10
Sundry Debtors
4,024.70
5,220.20
4,416.80
3,340.30
3,127.30
3,663.20
3,950.80
3,206.30
2,277.50
1,746.60
Cash & Bank
2,956.80
1,105.10
573.10
1,106.90
888.30
964.90
548.90
1,314.90
1,543.50
638.70
Other Current Assets
1,269.50
664.20
274.00
229.90
1,265.30
1,085.50
1,080.50
1,019.20
348.50
358.90
Short Term Loans & Adv.
717.30
735.90
711.70
1,345.50
1,003.00
874.50
806.10
730.10
268.50
234.80
Net Current Assets
8,004.50
6,080.10
4,481.50
4,268.40
854.70
446.00
1,155.60
2,128.50
716.50
819.40
Total Assets
34,857.90
27,555.00
24,485.80
26,533.40
22,810.30
22,833.70
22,512.80
17,111.50
14,325.20
10,032.10

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
6,776.70
3,196.30
2,688.80
2,104.50
3,293.90
2,931.50
1,281.90
919.30
1,311.70
1,893.50
PBT
6,026.70
4,838.10
2,582.70
5,232.30
2,284.80
1,495.40
2,382.10
2,312.00
1,611.90
2,098.70
Adjustment
1,020.40
546.70
933.90
-2,117.20
1,163.00
1,474.40
539.10
624.30
333.70
249.80
Changes in Working Capital
1,531.50
-902.70
-235.80
-336.00
191.10
263.80
-971.70
-1,383.90
-411.20
271.70
Cash after chg. in Working capital
8,578.60
4,482.10
3,280.80
2,779.10
3,638.90
3,233.60
1,949.50
1,552.40
1,534.40
2,620.20
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,801.90
-1,285.80
-592.00
-674.60
-345.00
-302.50
-675.40
-602.30
-237.60
-646.00
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.40
7.80
-30.80
14.90
-80.70
Cash From Investing Activity
-8,372.30
-1,475.20
1,535.00
-1,000.30
-724.60
-1,012.30
-4,238.70
-973.70
-2,871.90
-863.50
Net Fixed Assets
-776.80
-572.20
-669.30
-490.20
-462.80
-289.60
-1,652.30
-600.20
-557.40
-531.50
Net Investments
-4,208.50
-2,403.70
238.70
1,352.60
-66.50
-2,208.90
-577.10
305.60
-1,606.20
-108.40
Others
-3,387.00
1,500.70
1,965.60
-1,862.70
-195.30
1,486.20
-2,009.30
-679.10
-708.30
-223.60
Cash from Financing Activity
2,014.20
-1,778.80
-4,400.40
-868.30
-2,547.70
-1,528.20
1,884.60
51.50
2,315.80
-934.80
Net Cash Inflow / Outflow
418.60
-57.70
-176.60
235.90
21.60
391.00
-1,072.20
-2.90
755.60
95.20
Opening Cash & Equivalents
413.00
487.80
657.80
888.30
1,177.70
778.80
1,589.70
1,592.60
837.00
737.90
Closing Cash & Equivalent
826.80
413.00
487.80
1,106.90
1,087.20
1,177.70
778.80
1,589.70
1,592.60
837.00

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
238.10
197.11
173.08
166.01
126.88
101.33
101.43
85.40
67.97
55.66
ROA
14.77%
14.70%
7.82%
9.40%
9.66%
5.18%
9.34%
11.11%
12.18%
20.14%
ROE
21.08%
20.52%
11.60%
15.51%
18.88%
11.32%
19.36%
22.26%
23.43%
38.62%
ROCE
26.06%
24.90%
13.64%
15.30%
14.23%
10.02%
15.89%
18.41%
16.50%
28.60%
Fixed Asset Turnover
2.20
1.98
1.88
1.69
1.69
0.88
1.05
1.38
1.38
1.76
Receivable days
36.93
46.37
41.75
39.94
42.92
97.49
99.21
83.37
76.72
63.29
Inventory Days
29.51
32.98
38.39
42.95
38.08
70.13
70.33
63.69
59.88
54.52
Payable days
151.33
147.51
145.80
166.64
189.45
64.85
68.81
68.11
74.18
65.30
Cash Conversion Cycle
-84.89
-68.16
-65.67
-83.76
-108.45
102.77
100.73
78.94
62.42
52.51
Total Debt/Equity
0.13
0.04
0.07
0.25
0.35
0.77
0.76
0.62
0.75
0.43
Interest Cover
32.55
60.22
20.94
23.35
16.11
5.38
13.17
21.87
26.55
40.75

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Zydus Lifesciences gets USFDA’s approval for Ivermectin Tablets, Dapsone Tablets
    28th Feb 2026, 16:42 PM

    The group now has 434 approvals and has so far filed 505 ANDAs since the commencement of the filing process in FY 2003-04

    Read More
  • Zydus Lifesciences to launch Semaglutide injection in India
    26th Feb 2026, 10:08 AM

    A critical differentiator of Zydus’ Semaglutide offering will be its novel, indigenously developed drug-delivery system

    Read More
  • USFDA concludes Pre-Approval inspection at Zydus Lifesciences’ Ahmedabad facility
    20th Feb 2026, 10:07 AM

    The inspection closed with Nil observations

    Read More
  • Zydus Lifesciences launches Anyra for advancing ophthalmic care
    19th Feb 2026, 10:59 AM

    With this launch, the company reinforces its commitment to advancing ophthalmic care and expanding access to high-quality, affordable biologics for patients across India

    Read More
  • Zydus Lifesciences gets nod for Bosentan tablets
    19th Feb 2026, 09:50 AM

    Bosentan 32 mg tablets will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad

    Read More
  • Zydus Lifesciences launches Pepair
    17th Feb 2026, 11:42 AM

    Pepair is being launched in agreement with AeroDel Technology Innovations, an Indian medical device company focused on simplifying inhalation through drug-delivery, pulmonary rehabilitation

    Read More
  • Zydus Lifesciences gets USFDA’s final approval for Ammonium Lactate Cream
    14th Feb 2026, 11:51 AM

    The group now has 430 approvals and has so far filed 505 ANDAs since the commencement of the filing process in FY 2003-04

    Read More
  • Zydus Lifesciences - Quarterly Results
    10th Feb 2026, 00:00 AM

    Read More
  • Zydus Lifesciences reports marginal rise in Q3 consolidated net profit
    9th Feb 2026, 16:14 PM

    Total consolidated income of the company increased by 30.96% at Rs 6975.90 crore for Q3FY26

    Read More
  • Zydus Lifesciences secures USFDA Orphan Drug Designation for Desidustat
    6th Feb 2026, 14:20 PM

    The company has received ODD for Desidustat for the treatment of Sickle Cell Disease

    Read More
  • Zydus Lifesciences gets USFDA’s tentative nod for Dapagliflozin tablets
    4th Feb 2026, 17:15 PM

    Dapagliflozin tablets will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad

    Read More
  • USFDA conducts inspection at Zydus group’s Unit-2 manufacturing plant at Ankleshwar
    24th Jan 2026, 15:10 PM

    The company will closely work with the USFDA to address the observations expeditiously

    Read More
  • Zydus Lifesciences launches Nivolumab biosimilar ‘Tishtha’ in India
    22nd Jan 2026, 11:17 AM

    Tishtha will be available in 100 mg and 40 mg dosages priced at Rs 28,950 and Rs 13,950 respectively

    Read More
  • Zydus Lifesciences gets USFDA’s final nod for Eltrombopag Tablets
    16th Jan 2026, 10:39 AM

    Eltrombopag tablets will be produced at the group’s formulation manufacturing facility at SEZ, Ahmedabad

    Read More
  • Zydus Lifesciences’ arm gets USFDA’s nod for ZYCUBO
    13th Jan 2026, 10:51 AM

    This is the first and only treatment approved for Menkes disease, a rare and fatal genetic condition, in the United States

    Read More
  • Zydus Lifesciences’ arm enters into strategic partnership with Bioeq AG
    24th Dec 2025, 09:50 AM

    The Biologics License Application for NUFYMCO has been approved by USFDA on December 18, 2025

    Read More
  • Zydus Lifesciences inks pact with Myriad Genetics
    19th Dec 2025, 12:21 PM

    The company will exclusively market, create awareness, access and engage clinicians on three of Myriad Genetics’ broadly validated diagnostic platforms

    Read More
  • Zydus Lifesciences’ arm receives USFDA’s acceptance for CUTX-101 NDA resubmission
    16th Dec 2025, 14:43 PM

    The resubmission has been accepted as a Class I response and as a result, the company has received January 14, 2026 as the new PDUFA date

    Read More
  • Zydus Lifesciences launches Denosumab biosimilar ‘Zyrifa’
    10th Dec 2025, 12:38 PM

    ‘Zyrifa’ is priced at MRP of Rs 12,495

    Read More
  • Zydus Lifesciences’ arm joins hands with Formycon AG for biosimilar of Keytruda
    10th Dec 2025, 10:50 AM

    Zydus Lifesciences Global FZE, United Arab Emirates has entered into a strategic partnership with Formycon AG

    Read More
  • Zydus Lifesciences gets EIR from USFDA for Jarod injectable facility
    4th Dec 2025, 15:59 PM

    This inspection was conducted following the warning letter issued on August 29, 2024 by the USFDA

    Read More
  • Zydus Lifesciences gets USFDA’s tentative nod for Empagliflozin and Linagliptin Tablets
    28th Nov 2025, 10:12 AM

    Empagliflozin and Linagliptin Tablets had annual sales of $215.8 million in the United States

    Read More
  • Zydus Lifesciences inks exclusive licensing and commercialization pact with RK Pharma Inc
    26th Nov 2025, 14:59 PM

    Under this pact, RK Pharma will manufacture and supply the finished product, while the company will be responsible for the NDA submission and commercialization of the product in the US

    Read More
  • Zydus Lifesciences gets final nod for Verapamil Hydrochloride Extended Release Tablets
    26th Nov 2025, 10:13 AM

    Verapamil Hydrochloride Extended-Release Tablets will be produced at Zydus Lifesciences, Baddi, Himachal Pradesh

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.